Related Experiment Video
Updated: Apr 19, 2026

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
Published on: March 27, 2018
Dopamine D3 receptor agonists as pharmacological tools
S Kassel1, J S Schwed1, H Stark1
1Heinrich-Heine-University, Universitaetsstr. 1, 40225 Duesseldorf, Germany.
This review details dopamine D3 receptor agonists, classifying ergoline and non-ergoline compounds. It examines their pharmacodynamics, species differences, and signaling mechanisms to aid in selecting optimal drug candidates for neurological disorders.
Area of Science:
- Neuroscience
- Pharmacology
- Medicinal Chemistry
Background:
- Dopaminergic system dysregulation is implicated in neurological disorders such as Parkinson's disease, restless legs syndrome, and schizophrenia.
- Dopamine D3 receptors are recognized as a crucial therapeutic target for these conditions, but their pharmacological profiles require further elucidation.
Purpose of the Study:
- To review and categorize dopamine D3 receptor full agonists, focusing on both ergoline and non-ergoline chemical subclasses.
- To provide a comprehensive overview of their pharmacodynamic properties, including affinity, selectivity, and efficacy across different signaling mechanisms and species.
Main Methods:
- Systematic review and classification of ergoline and non-ergoline dopamine D3 receptor agonists.
- Analysis of pharmacodynamic data, including receptor binding, functional assays, and species-specific responses.
- Evaluation of structure-activity relationships for different chemical classes of ligands.
Main Results:
- Detailed description of various chemical subclasses of dopamine D3 receptor agonists.
- Characterization of their interactions with related receptors and functional effects on signaling pathways.
- Highlighting of species differences in receptor pharmacology.
Conclusions:
- This review consolidates critical pharmacological data on dopamine D3 receptor agonists.
- It provides essential information to guide the rational selection of compounds with optimal affinity, selectivity, and efficacy for therapeutic development in neurological disorders.
More Related Videos
11:26Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake
Published on: September 21, 2017
09:44Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
Related Concept Videos
Drugs Affecting Neurotransmitter Synthesis
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Direct-Acting Cholinergic Agonists: Pharmacological Actions